| Literature DB >> 28187278 |
Matthew B Yurgelun1, Georgia Chenevix-Trench2, Scott M Lippman3.
Abstract
Study of the biology of tumors caused by germline mutations has led to recent paradigm-changing therapy and is driving precision prevention efforts, including immune oncology and early detection research. Here, we explore recent biologic advances that are redefining the spectrum of cancers linked to various hereditary predisposition syndromes and can be leveraged to improve personalized risk assessment and develop novel interventions to prevent or intercept cancer.Entities:
Mesh:
Year: 2017 PMID: 28187278 DOI: 10.1016/j.cell.2017.01.031
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 66.850